|
Complete hydatidiform mole
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
All CM cases showed absent (<10%) p57 IHC in chorionic villi.
|
30394942 |
2020 |
|
Complete hydatidiform mole
|
0.100 |
Biomarker
|
disease |
BEFREE |
Abnormal chorionic villi were seen in all cases with histomorphological and/or p57 immunohistochemical features simulating either partial or complete mole.
|
30952972 |
2019 |
|
Complete hydatidiform mole
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We compared the allele zygosity ratio in 11 nonmolar donor egg POC, 5 dispermic (heterozygous) CHM and 31 monospermic (homozygous) CHM, without knowledge of the use of a donor egg, the histologic findings, or results of p57 immunohistochemical staining.
|
28463912 |
2018 |
|
Complete hydatidiform mole
|
0.100 |
Biomarker
|
disease |
BEFREE |
Immunohistochemistry p57 demonstrated negative staining in the villous stromal and cytotrophoblastic cells, supporting the diagnosis of CHM.
|
28800576 |
2017 |
|
Complete hydatidiform mole
|
0.100 |
Biomarker
|
disease |
BEFREE |
Detailed histomorphological review along with p57 IHC was carried out in 28 diagnosed cases (23 CM, 4 PM and 1 molar pregnancy not categorized) and 25 controls of four normal placentas and 21 POC (8 non-hydropic and 13 HA).
|
28574027 |
2017 |
|
Complete hydatidiform mole
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In a prospective series of 1024 products of conception specimens subjected to immunohistochemical analysis of p57 expression and molecular genotyping with short tandem-repeat markers, 288 CHMs were diagnosed, of which 126 were genotyped, including 16 invasive CHMs.
|
26535984 |
2016 |
|
Complete hydatidiform mole
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Of the 14 androgenetic/biparental mosaics with discordant p57 expression, 6 were uniformly mosaic and 8 had a p57-negative androgenetic molar component. p57 expression is highly correlated with genotyping, serves as a reliable marker for diagnosis of complete hydatidiform moles, and identifies androgenetic cell lines in mosaic conceptions.
|
23887308 |
2014 |
|
Complete hydatidiform mole
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Recognition of their distinctive p57 expression patterns and genotyping results can prevent misclassification as typical CHMs, PHMs, or nonmolar specimens.
|
23370656 |
2013 |
|
Complete hydatidiform mole
|
0.100 |
Biomarker
|
disease |
BEFREE |
Correct classification of all cases combined ranged from 51% to 75% by morphology and 70% to 80% with p57, with statistically significantly better performance of faculty only in round 2 (P-values of 0.69, <0.01, and 0.15 for rounds 1 to 3, respectively). p57 immunostaining significantly improved recognition of CHMs (P<0.01) and had high reproducibility (κ=0.93 to 0.96) but had no impact on distinction of PHMs and NMs.
|
22992698 |
2012 |
|
Complete hydatidiform mole
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cases were classified by 3 gynecologic pathologists on the basis of H&E slides (masked to p57 immunostaining and genotyping results) into 1 of 3 categories (CHM, PHM, or NM) during 2 diagnostic rounds; a third round incorporating p57 immunostaining results was also conducted.
|
22245958 |
2012 |
|
Complete hydatidiform mole
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Although p57 immunostaining alone can identify CHMs, which lack p57 expression because of the lack of maternal DNA, this analysis cannot distinguish PHMs from nonmolar specimens as both express p57 because of the presence of maternal DNA.
|
21293291 |
2011 |
|
Complete hydatidiform mole
|
0.100 |
Biomarker
|
disease |
BEFREE |
These data suggest that the combination of p57 and FISH seems to be the best ancillary testing strategy to aid pathologists in the appropriate identification of CM, PM, and HA in POC specimens.
|
20093228 |
2010 |
|
Complete hydatidiform mole
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Specimens with morphologic features suggestive of CHM yet retaining p57 expression should be subjected to molecular genotyping to establish a definitive diagnosis because misclassification as PHM underestimates the risk of persistent gestational trophoblastic disease.
|
19542869 |
2009 |